Korneal Neovaskülarizasyon Yayın Eğilimleri: Bibliometrik ve Görselleştirilmiş Analiz
Yıl 2025,
Cilt: 9 Sayı: 2, 251 - 258, 08.08.2025
Nejat Ünlükal
,
Serhat Eker
,
Hakan Serin
,
Ender Erdoğan
Öz
Amaç: Mekanik yaralanma, kimyasal yanıklar, inflamasyon ve/veya limbal kök hücre eksikliği kornea neovaskülarizasyonuna (KNV) neden olabilir. Bu çalışmada KNV'deki bilgi kapsamını, odaklanılan konuları ve ortaya çıkan araştırmalardaki eğilimleri göstermeyi amaçladık.
Araçlar ve Yöntem: Ocak 1980 ile Mart 2024 arasında Web of Science Core Collection'da yayımlanan tüm KNV araştırma makaleleri, editöre mektuplar, vaka raporları, incelemeler ve bildiriler değerlendirildi. Elde edilen literatür çalışmaları, R sürüm 4.2.3'teki "bibliometrix" paketi ile toplandı ve analiz edildi. Referansların eş atıf analizi ve anahtar kelimelerin eş oluşum analizi kullanılarak temel ve önemli noktalar belirlendi ve böylece bu alan hakkında genel bir bakış elde edildi.
Bulgular: Toplamda 1439 adet KNV hakkında makale toplandı, bunların çoğu Amerika Birleşik Devletleri ve Çin'de yayınlandı. En fazla makale yayınlayan kuruluş Harvard Üniversitesi olduğu görüldü. Cursiefen C ve Bock F KNV hakkında bildirileri olan en etkili yazarlardı. Investigative Ophthalmology & Visual Science en yüksek H-indeksine ve yayın sayısına sahip dergi olarak saptandı. En fazla yayını olan ikinci dergi Cornea oldu. Toplam KNV yayın sayısı 1980 yılından 2013 yılına ortalama atıf sayısı 26.72 idi. Investigative Ophthalmology & Visual Science, dergiler arasındaki toplam atıf sayısına göre listenin başında yer aldı (n=10505).
Sonuç: Mevcut çalışma, KNV araştırmalarının giderek akademisyenlerin ve araştırmacıların ilgisini çektiğini göstermektedir.
Kaynakça
-
1. DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588-598.
-
2. Nicholas MP, Mysore N. Corneal neovascularization. Exp Eye Res. 2021;202:108363.
-
3. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12 (4):242-249.
-
4. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. 2009;24(3):139-148.
-
5. Lee P, Wang CC, Adamis AP. Ocular neovascular ization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245-269.
-
6. Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis (Lond). 2017; 4(1):28.
-
7. Inomata T, Mashaghi A, Di Zazzo A, Lee SM, Chiang H, Dana R. Kinetics of angiogenic responses in corneal transplantation. Cornea. 2017;36(4):491-496.
-
8. Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019;63(1):15-22.
-
9. Gupta D, Illingworth C. Treatments for corneal neovascularization: A review. Cornea. 2011;30(8): 927-938.
-
10. Roshandel D, Eslani M, Baradaran-Rafii A, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16(4):398-414.
-
11. Cooper ID. Bibliometrics basics. J Med Libr Assoc. 2015;103(4):217-218.
-
12. Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J. Informetr. 2017;11(4):959-975.
-
13. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J. Bus. Res. 2021;133:285-96.
-
14. Ozturk O, Kocaman R, Kanbach DK. How to design bibliometric research: an overview and a framework proposal. Rev. Manag. Sci. 2024;18(11):3333-3361.
-
15. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):1221-1234.
-
16. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99(3):403-414.
-
17. Qazi Y, Hamrah P. Corneal Allograft Rejection: Immunopathogenesis to therapeutics. J Clin Cell Immunol. 2013;2013(9):6.
-
18. Chang J-H, Garg NK, Lunde E, Han K-Y, Jain S, Azar DT. Corneal neovascularization: An anti-vegf therapy review. Surv Ophthalmol. 2012;57(5):415-429.
-
19. Fasciani R, Mosca L, Giannico MI, Ambrogio SA, Balestrazzi E. Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival. Int Ophthalmol. 2015;35(2):221-227.
-
20. Clements JL, Dana R. Inflammatory Corneal Neovascularization: Etiopathogenesis. Semin Ophthalmol. 2011;26(4-5):235-245.
-
21. Mcnatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo cam and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther. 1999;15(5):413-423.
-
22. Goktas S, Sakarya R, Erdogan E, et al. Antiangiogenic effect of itraconazole on corneal neovascularization: a pilot experimental investigation. Ophthalmic Res. 2014;52(4):170-174.
-
23. Goktas S, Erdogan E, Sakarya R, et al. Inhibition of corneal neovascularization by topical and subconjunctival tigecycline. J Ophthalmol. 2014;2014 (1):452685.
-
24. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769-777.
-
25. Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocul Surf. 2011;9(4):227-237.
-
26. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp. 2009;247(10):1375-1382.
-
27. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci. 2011;52(12):8718-8723.
Publication Trends in Corneal Neovascularization: A Bibliometric and Visualized Analysis
Yıl 2025,
Cilt: 9 Sayı: 2, 251 - 258, 08.08.2025
Nejat Ünlükal
,
Serhat Eker
,
Hakan Serin
,
Ender Erdoğan
Öz
Purpose: Mechanical injury, alkali and acid injury of the cornea, inflammation and/or dysfunction of the corneal epithelial stem/progenitor cells can cause corneal neovascularization (CNV). We aimed to demonstrate the knowledge elements, focused topics, and recent interests in emerging research in CNV.
Materials and Methods: The CNV research documents, reviews, case reports and proceedings papers issued between January 1980 and March 2024 on the Web of Science Core Collection were gathered. The retrieved literature was collected and analyzed by the “bibliometrix” package in R version 4.2.3. Basic and important points were determined by using bibliographic coupling, co-citation and co-word analysis, thus obtaining a general overview of this field.
Results: A total of 1439 articles on CNV were achieved, most of which were featured in the United States and China. The institution that reported the most publications was the Harvard University. Cursiefen C and Bock F were the most dominant authors about CNV. The Investigative Ophthalmology & Visual Science had the highest H-index and most publications. The second journal with the most publications was Cornea. The overall number of CNV publications raised from the year 1980 to 2013. The mean citation count per CNV document was 26.72. Investigative Ophthalmology & Visual Science was the leading journal at the list based on the total number of citations (n=10505).
Conclusions: The current study shows that the research interest of CNV is progressively growing the attention of scholars and researchers.
Etik Beyan
Ethics committee approval was not required for this study because there was no study on animals or humans.
Kaynakça
-
1. DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588-598.
-
2. Nicholas MP, Mysore N. Corneal neovascularization. Exp Eye Res. 2021;202:108363.
-
3. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12 (4):242-249.
-
4. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. 2009;24(3):139-148.
-
5. Lee P, Wang CC, Adamis AP. Ocular neovascular ization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245-269.
-
6. Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis (Lond). 2017; 4(1):28.
-
7. Inomata T, Mashaghi A, Di Zazzo A, Lee SM, Chiang H, Dana R. Kinetics of angiogenic responses in corneal transplantation. Cornea. 2017;36(4):491-496.
-
8. Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019;63(1):15-22.
-
9. Gupta D, Illingworth C. Treatments for corneal neovascularization: A review. Cornea. 2011;30(8): 927-938.
-
10. Roshandel D, Eslani M, Baradaran-Rafii A, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf. 2018;16(4):398-414.
-
11. Cooper ID. Bibliometrics basics. J Med Libr Assoc. 2015;103(4):217-218.
-
12. Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J. Informetr. 2017;11(4):959-975.
-
13. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J. Bus. Res. 2021;133:285-96.
-
14. Ozturk O, Kocaman R, Kanbach DK. How to design bibliometric research: an overview and a framework proposal. Rev. Manag. Sci. 2024;18(11):3333-3361.
-
15. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):1221-1234.
-
16. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99(3):403-414.
-
17. Qazi Y, Hamrah P. Corneal Allograft Rejection: Immunopathogenesis to therapeutics. J Clin Cell Immunol. 2013;2013(9):6.
-
18. Chang J-H, Garg NK, Lunde E, Han K-Y, Jain S, Azar DT. Corneal neovascularization: An anti-vegf therapy review. Surv Ophthalmol. 2012;57(5):415-429.
-
19. Fasciani R, Mosca L, Giannico MI, Ambrogio SA, Balestrazzi E. Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival. Int Ophthalmol. 2015;35(2):221-227.
-
20. Clements JL, Dana R. Inflammatory Corneal Neovascularization: Etiopathogenesis. Semin Ophthalmol. 2011;26(4-5):235-245.
-
21. Mcnatt LG, Weimer L, Yanni J, Clark AF. Angiostatic activity of steroids in the chick embryo cam and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther. 1999;15(5):413-423.
-
22. Goktas S, Sakarya R, Erdogan E, et al. Antiangiogenic effect of itraconazole on corneal neovascularization: a pilot experimental investigation. Ophthalmic Res. 2014;52(4):170-174.
-
23. Goktas S, Erdogan E, Sakarya R, et al. Inhibition of corneal neovascularization by topical and subconjunctival tigecycline. J Ophthalmol. 2014;2014 (1):452685.
-
24. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769-777.
-
25. Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocul Surf. 2011;9(4):227-237.
-
26. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp. 2009;247(10):1375-1382.
-
27. Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci. 2011;52(12):8718-8723.